Dogwood Therapeutics, Inc. (NASDAQ:DWTX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Dogwood Therapeutics, Inc.

Home
Companies
Dogwood Therapeutics, Inc.

BRIEF

published on 12/02/2025 at 14:05, 2 days 14 hours ago

Dogwood Therapeutics Seeks Extended Exclusivity with New Halneuron® Patent

Intellectual Property Phase 3 Development Dogwood Therapeutics Halneuron® Synthetic Manufacturing
PRESS RELEASE

published on 12/02/2025 at 14:00, 2 days 14 hours ago

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Dogwood Therapeutics files new IP for synthetic Halneuron® with extended exclusivity period. Phase 3 development uses innovative synthetic process for cost efficiency

Biotechnology Intellectual Property Phase 3 Development Dogwood Therapeutics Synthetic Halneuron
BRIEF

published on 11/11/2025 at 14:50, 23 days 13 hours ago

Dogwood Therapeutics Reaches Milestone in Halneuron Phase 2b Trial

Clinical Trial Progress Dogwood Therapeutics Halneuron Phase 2b Chemotherapy-induced Pain Biotechnology Update
PRESS RELEASE

published on 11/11/2025 at 14:45, 23 days 13 hours ago

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Dogwood Therapeutics reports low early termination rate in ongoing HALT-CINP Phase 2b trial for Halneuron® vs placebo in cancer patients with chemotherapy-induced neuropathy. Recruitment on track with 100 patients enrolled for study evaluation

Clinical Trial Dogwood Therapeutics Halneuron® HALT-CINP Chemotherapy-induced Neuropathic Pain
BRIEF

published on 10/30/2025 at 14:20, 1 month 5 days ago

Dogwood Therapeutics to Announce Q3 2025 Financial Results

Biotechnology Dogwood Therapeutics Halneuron® Q3 2025 Financial Results SP16 IV
PRESS RELEASE

published on 10/30/2025 at 14:15, 1 month 5 days ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Dogwood Therapeutics, Inc. to report Q3 2025 financial results, focusing on new medicines for pain and neuropathy. Lead candidate Halneuron® in Phase 2b development for treating CINP

Dogwood Therapeutics Q3 2025 Financial Results New Medicines Pain Neuropathy
BRIEF

published on 10/14/2025 at 14:50, 1 month 21 days ago

Dogwood Therapeutics to Present at Maxim Growth Summit 2025

Dogwood Therapeutics Halneuron® Maxim Growth Summit Greg Duncan SP16 IV Trial
PRESS RELEASE

published on 10/14/2025 at 14:45, 1 month 21 days ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
Dogwood Therapeutics CEO Greg Duncan to participate at Maxim Growth Summit in NYC to discuss new medicines for pain and neuropathic disorders. Company develops non-opioid analgesic program and antiviral program

Dogwood Therapeutics Maxim Growth Summit Greg Duncan Pain Treatment Neuropathic Disorders
BRIEF

published on 10/07/2025 at 14:50, 1 month 28 days ago

Dogwood Therapeutics Presents Halneuron® Program at Annual Summit

Biotechnology Clinical Trials Pain Management Dogwood Therapeutics Halneuron®
PRESS RELEASE

published on 10/07/2025 at 14:45, 1 month 28 days ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
Dogwood Therapeutics announces presentation on Halneuron® pain management research program at Pain Therapeutics Summit. Developing non-opioid analgesics for cancer pain relief

Clinical Trials Pain Management Non-opioid Analgesics Dogwood Therapeutics Halneuron

Accesswire

Published on 12/05/2025 at 02:35, 1 hour 53 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 1 hour 58 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 3 hours 28 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 23 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 28 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 37 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 13 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 17 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 10 hours 28 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 43 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 27 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE